1.Development of Dignity Individual Music Therapy Program “Your Important Melody”
Yoshihiko SAKASHITA ; Ritsuko NAGASHIMA ; Masami FUJISATO
Palliative Care Research 2020;15(2):111-116
Introduction: Although spiritual care is one of the challenges of palliative care, structured interventions are limited. We report on the original development of the Dignity Individual Music Therapy Program (DMT) incorporating the elements of Dignity Therapy (DT) for spiritual care. Program: Developed by a research group including a music therapist based on the experience of DT. Procedure: First, the patient selects important songs based on questions such as "When did you live the most in your life? Are there any songs that remind you of those days?" Next, a music therapist plays the music on a piano in a hospital room (individual concert). Encourage the patient to talk freely about their thoughts and life episodes after the performance. Discussion: Patients who have performed DMT have been very well received. Because it is a structured program, it can be implemented in various places. The utility and feasibility of spiritual care will be investigated.
2.Analysis of the Risk of Injection Incompatibilities in the ICU and Pharmacistsʼ Contribution toward Avoiding Such Incompatibilities
Koji SHINOZAKI ; Yoshinori INANO ; Miyuki TAKEUCHI ; Yoshihiko CHIBA ; Hiromitsu NAKASA
Japanese Journal of Drug Informatics 2019;21(1):27-33
Objective: Avoiding injection incompatibilities is important. At our hospital, pharmacists are present at the intensive care unit (ICU),where they manage drip lines and use a lookup table for injection incompatibilities. We assessed the risk of injection incompatibilities in the ICU and the contribution of pharmacists toward their avoidance.Methods: We investigated the number of injections and main drip lines used for outpatients admitted to the general ward and ICU from an emergency setting. We further investigated inappropriate drip line conditions, subsequent interventions by pharmacists, and the actual number of injection incompatibilities. The investigation period lasted 1 year from April 2016 onward.Results: The number of injections and drip lines used in the ICU was significantly higher than that used in the general ward (p<0.001). Patients in the ICU received multiple continuous intravenous injections from one drip line despite the number of main drip lines being high. Even using the lookup table, 78.3% inquiries made by nurses were related to injection incompatibilities. Fourteen inappropriate drip lines selected by nurses were associated with a risk of injection incompatibility; these occurred during the absence of pharmacists and involved a combination of continuous intravenous injections to be administered from a side line. Subsequently,pharmacists intervened and avoided injection incompatibilities. There was no report of injection incompatibilities in the ICU.Conclusion: At ICU, the risk of injection incompatibilities is high and it is necessary to focus on the combination of injections to be administered from main drip lines and side lines as well as incompatibilities of multiple continuous intravenous injections to be administered from side lines. A lookup table is insufficient to avoid injection incompatibilities. Therefore, pharmacists can contribute to avoiding injection incompatibilities by maintaining constant presence in the ICU, designing drip line layouts, and proposing line selections.
4.Switching to systemic therapy after locoregionaltreatment failure: Definition and best timing
Sadahisa OGASAWARA ; Yoshihiko OOKA ; Keisuke KOROKI ; Susumu MARUTA ; Hiroaki KANZAKI ; Kengo KANAYAMA ; Kazufumi KOBAYASHI ; Soichiro KIYONO ; Masato NAKAMURA ; Naoya KANOGAWA ; Tomoko SAITO ; Takayuki KONDO ; Eiichiro SUZUKI ; Shingo NAKAMOTO ; Akinobu TAWADA ; Tetsuhiro CHIBA ; Makoto ARAI ; Jun KATO ; Naoya KATO
Clinical and Molecular Hepatology 2020;26(2):155-162
In patients with unresectable hepatocellular carcinoma (HCC) without both macrovascular invasion and extrahepatic metastasis, the initial treatment choice recommended is transarterial chemoembolization (TACE). Before sorafenib came into wide use, TACE had been pointlessly carried out repeatedly. It was in the early 2010s that the concept of TACE refractory was advocated. Two retrospective studies from Japan indicated that conversion from TACE to sorafenib the day after patients were deemed as TACE refractory improved overall survival compared with continued TACE, according to the definition by the Japan Society of Hepatology. Nowadays, phase 3 trials have shown clinical benefits of several novel molecular target agents. Compared with the era of sorafenib, sequential treatments with these molecular target agents have gradually prolonged patients’ survival and have become major strategies in patients with HCC. Taking these together, conversion from TACE to systemic therapies at the time of TACE refractory, compared with before, may have a greater impact on survival and may be considered deeper in the decisions-making process in patients with unresectable HCC who are candidate for TACE. Up-to-date information on the concept of TACE refractory is summarized in this review. We believe that the survival of patients with unresectable HCC without both macrovascular invasion and extrahepatic metastasis may be dramatically improved by optimal timing of TACE refractory and switching to systemic therapies.
5.Short and Long-Term Outcomes of Diabetes Mellitus in Patients with Autoimmune Pancreatitis after Steroid Therapy.
Yuji MIYAMOTO ; Terumi KAMISAWA ; Taku TABATA ; Seiichi HARA ; Sawako KURUMA ; Kazuro CHIBA ; Yoshihiko INABA ; Go KUWATA ; Takashi FUJIWARA ; Hideto EGASHIRA ; Koichi KOIZUMI ; Ryoko SEKIYA ; Junko FUJIWARA ; Takeo ARAKAWA ; Kumiko MOMMA ; Toru ASANO
Gut and Liver 2012;6(4):501-504
BACKGROUND/AIMS: Autoimmune pancreatitis (AIP) is frequently associated with diabetes mellitus (DM). This study evaluated the effect of steroid therapy on the course of DM in AIP. METHODS: Glucose tolerance was examined in 69 patients with AIP. DM onset was classified as either a simultaneous onset with AIP or an exacerbation of pre-existing DM. Based on the changes in the HbA1c levels and insulin dose, the responses of DM to steroids were classified as improved, no change, or worsened. RESULTS: Thirty (46%) patients were diagnosed as having DM (simultaneous onset, n=17; pre-existing, n=13). Three months after starting the steroid treatment, the DM improved in 13 (54%) of 24 DM patients. The DM improved in 55%, had no change in 36%, and worsened in 9% of the 11 simultaneous onset DM patients, and it improved in 54%, had no change in 31%, and worsened in 15% of the 13 pre-existing DM patients. At approximately 3 years after starting the steroid treatment, the DM improved in 10 (63%) of 16 patients. The pancreatic exocrine function improved in parallel with the changes in the DM in seven patients. CONCLUSIONS: Because approximately 60% of DM associated with AIP is responsive to steroids in the short- and long-terms, marked DM associated with AIP appears to be an indication for steroid therapy.
Diabetes Mellitus
;
Glucose
;
Humans
;
Insulin
;
Pancreatitis
;
Steroids